Partnership for Cures

Delivering More Treatments to More Patients More Quickly

aka Cures Within Reach   |   CHICAGO, IL   |  www.cureswithinreach.org

Mission

Cures Within Reach improves patient quality and length of life by leveraging the unrealized clinical potential and missed therapeutic opportunities of existing medicine and science. We leverage the speed, safety and cost-effectiveness of medical repurposing research, driving more treatments to more patients more quickly by clinically testing approved drugs, devices and nutraceuticals for unsolved disease indications that serve commercial and/or philanthropic need.

Notes from the nonprofit

The more we work together, the sooner we can drive more treatments to more patients more quickly through Repurposing Research.

Ruling year info

2005

President and CEO

Barbara Goodman

Main address

134 N. LaSalle St #1130

CHICAGO, IL 60602 USA

Show more contact info

EIN

20-3620169

NTEE code info

Medical Specialty Research (H90)

Fund Raising and/or Fund Distribution (G12)

Research Institutes and/or Public Policy Analysis (E05)

IRS filing requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Sign in or create an account to view Form(s) 990 for 2020, 2019 and 2018.
Register now

Communication

Programs and results

What we aim to solve

SOURCE: Self-reported by organization

There are 7000+ unsolved diseases, and de novo drug discovery can't provide affordable treatments for all of these. Drug and other therapeutic repurposing can provide "new" therapies, but there is a lack of economic incentives and governmental programs to encourage drug and other repurposing.

Our programs

SOURCE: Self-reported by organization

What are the organization's current programs, how do they measure success, and who do the programs serve?

Proof of Concept Clinical Trials

These studies test new hypotheses for disease treatment and require initial funding of $35,000-100,000. They include pilot clinical trials in unsolved disease testing drugs, devices, nutraceuticals and diagnostics already approved for human use.

Population(s) Served
People with diseases and illnesses

CureAccelerator is the World’s First Online, Interactive Platform
 For Repurposing Research. CureAccelerator supports "proof of concept” research repurposing drugs, devices and nutriceuticals already approved for human use. On CureAccelerator, funders have direct access to repurposing research, researchers can post ideas and connect with peers and funding, and clinicians can contribute their experience of off-label use in need of validation. Using expertise, resources and dollars on hand, CureAccelerator is here so that we can all quickly and affordably answer the question "will this help patients?”

Population(s) Served
People with diseases and illnesses

Where we work

Awards

Fellowship in Social Entrepreneurship 2009

Ashoka

Goals & Strategy

SOURCE: Self-reported by organization

Learn about the organization's key goals, strategies, capabilities, and progress.

Charting impact

Four powerful questions that require reflection about what really matters - results.

Our goal is to create hundreds of "new" therapies through the repurposing of existing drugs, devices, nutriceuticals and diagnostics on a global basis. We want to create platforms for collaboration, and engines for economic support for Repurposing Research.

Strategy 1: Grow the CureAccelerator™ web platform to provide the collaboration tool and Repurposing Research marketplace that provides the many to many connections and ease of use for Repurposing Research to get funded and completed and delivered to patents.

Strategy 2: Create new economic engines for the repurposing of generic drugs for off-label use through social finance tools and through generic drug company partnerships that can support philanthropic funding, and through low profit commercialization that can support the regulatory approval for marketed generic drugs.

We already have developed CureAccelerator™ funded by a grant from the Robert Wood Johnson Foundation, and we now need to grow it.

We have structured and pursued the first social impact bond in England with our partners FindaCure and Numbers4Good. We have completed feasibility studies from the MaRS Centre funded by the Mindset Foundation and by Oliver Wyman supporting FindaCure.

We have support for the feasibility studies on the low profit commercialization program, and we have started discussions with generic drug companies.

We are supported by a Business Advisory Board comprised of senior staff from many of the stakeholders involved in Repurposing Research.

For over a decade, Cures WIthin Reach has found and funded over 85 repurposing research projects in over 50 institutions in 50 different diseases. This has resulted in supporting research that found 13 repurposed therapies for children with deadly diseases ALPS and FD, adults with multiple sclerosis, lung cancer, blood cancer, myelodysplastic syndrome and prostate cancer, and adult and children with type 1 and type 2 diabetes. Our $6 million in funding has helped to catalyze more than $49 million in follow-on funding - a strong leverage metric. We have a strong platform called CureAccelerator™ where researchers and clinicians submit their clinical repurposing research ideas for funding.

Financials

Partnership for Cures
lock

Unlock financial insights by subscribing to our monthly plan.

Subscribe

Unlock nonprofit financial insights that will help you make more informed decisions. Try our monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights?
Learn more about GuideStar Pro.

Operations

The people, governance practices, and partners that make the organization tick.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

Partnership for Cures

Board of directors
as of 1/26/2021
SOURCE: Self-reported by organization
Board chair

Margaret Christie

Margaret Christie

Golan Christie Taglia, LLC

Steve Braun

Northwestern Mutual Financial Network

Matt Rich

PWC

David Styler

Horizon Therapeutics

Lucy Mancini-Newell

Rob Metz

Armour Life Sciences

Nancy Sullivan

Illinois Ventures

Kristina Allikments

Takeda Pharma

Nicholas Manusos

Fuijifilm Pharmaceuticals

Board leadership practices

SOURCE: Self-reported by organization

GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section.

  • Board orientation and education
    Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations? Yes
  • CEO oversight
    Has the board conducted a formal, written assessment of the chief executive within the past year ? Yes
  • Ethics and transparency
    Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year? Yes
  • Board composition
    Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership? Yes
  • Board performance
    Has the board conducted a formal, written self-assessment of its performance within the past three years? Yes

Organizational demographics

SOURCE: Self-reported; last updated 1/5/2021,

Who works and leads organizations that serve our diverse communities? GuideStar partnered on this section with CHANGE Philanthropy and Equity in the Center.

Leadership

The organization's leader identifies as:

Race & ethnicity
White/Caucasian/European
Gender identity
Female
Sexual orientation
Heterosexual or Straight
Disability status
Person without a disability

Race & ethnicity

No data

Gender identity

 

Sexual orientation

No data

Disability